Early discontinuation of treatment for osteoporosis
Early discontinuation of treatment for osteoporosis
复制标题
DOI：
10.1016/s0002-9343(03)00362-0
复制
发表时间：
2003-08-15
影响因子：
5.9
通讯作者：
Ettinger, B
中科院分区：
文献类型：
--
作者：
Tosteson, ANA;Grove, MR;Ettinger, B
目得：为了确定与早期治疗中止的三个代理商，规定为妇女与低bone density.METHODS：一个电话调查进行了随机抽样的妇女年龄在45岁或以上的骨密度T-分数-1.0或更低，谁开始治疗激素替代疗法，雷洛昔芬，或阿仑膦酸钠在2000年至2001年。结果：在956名平均在治疗开始后7个月接受采访的妇女中，334名正在接受激素治疗，88名（26%）已经停止; 256名正在接受雷洛昔芬，48名（19%）已经停止366名患者正在服用阿仑膦酸钠，70名（19%）患者已停止服用（P = 0.02，与激素治疗相比）。有着烦人副作用的女性（有些困扰：比值比[OR] = 4.0; 95%置信区间[CI]：2.5 - 6.5;非常或极度困扰：OR = 25; 95% CI：16 - 39）或认为其骨密度测试结果未显示骨质疏松症（OR = 1.6; 95%CI：1.0 - 2.5）的女性更有可能停止治疗，与报告定期锻炼（OR = 0.7; 95%CI：0.4 - 1.0）或愿意服用处方药物（OR = 0.6; 95%CI：0.4 - 0.9）的女性相比。调整后的副作用和患者的特点，早期治疗中止的几率并没有显着差异treatment.CONCLUSION：提高坚持骨质疏松症治疗需要治疗的副作用最小化和妇女接受教育，就他们的骨密度测试结果。(C)2003年，Excerpta Medica Inc.
PURPOSE: To identify factors associated with early treatment discontinuation of three agents commonly, prescribed for women with low bone density.METHODS: A telephone survey was conducted in 2000 to 2001 in a random sample of women aged 45 years or older who had bone density T-scores -1.0 or lower and who had initiated treatment with hormone replacement therapy, raloxifene, or alendronate. Logistic regression was used to estimate adjusted odds ratios for early treatment discontinuation.RESULTS: Among 956 women who were interviewed an average of 7 months after treatment initiation, 334 were taking hormone therapy, and 88 (26%) had discontinued; 256 were taking raloxifene, and 48 (19%) had discontinued (P = 0.03 vs. hormone therapy); and 366 were taking alendronate, and 70 (19%) had discontinued (P = 0.02 vs. hormone therapy). Women with bothersome side effects (somewhat bothered: odds ratio [OR] = 4.0; 95% confidence interval [CI]: 2.5 to 6.5; very or extremely bothered: OR = 25; 95% CI: 16 to 39) or who thought that their bone density test results did not show osteoporosis (OR = 1.6; 95% CI: 1.0 to 2.5) were more likely to discontinue therapy, as compared with women reporting regular exercise (OR = 0.7; 95% CI: 0.4 to 1.0) or a willingness to take prescribed medications (OR = 0.6; 95% CI: 0.4 to 0.9). After adjustment for side effects and patient characteristics, the odds of early treatment discontinuation did not differ significantly among treatments.CONCLUSION: Improved adherence to osteoporosis treatment requires that treatment side effects be minimized and women be educated regarding their bone density test results. (C) 2003 by Excerpta Medica Inc.